Monotherapy or combination therapy in PsA: current aspects.
| Autor: | Skouvaklidou E; Department of Rheumatology, Fourth Department of Internal Medicine, Hippokration Hospital, Aristoteleio Panepistemio Thessalonikes, Thessaloniki, Greece., Avgerou P; Department of Rheumatology, Fourth Department of Internal Medicine, Hippokration Hospital, Aristoteleio Panepistemio Thessalonikes, Thessaloniki, Greece., Vassilakis KD; Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Fragoulis GE; Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, 17 Agiou Thoma Street, Athens 10679, Greece.; Institute of Infection, Immunity & Inflammation, University of Glasgow Institute of Infection Immunity and Inflammation, Glasgow, UK., Kougkas N; Department of Rheumatology, Fourth Department of Internal Medicine, Hippokration Hospital, Aristoteleio Panepistemio Thessalonikes, Thessaloniki, Greece. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Therapeutic advances in musculoskeletal disease [Ther Adv Musculoskelet Dis] 2024 Sep 18; Vol. 16, pp. 1759720X241274055. Date of Electronic Publication: 2024 Sep 18 (Print Publication: 2024). |
| DOI: | 10.1177/1759720X241274055 |
| Abstrakt: | Psoriatic arthritis (PsA) is an immune-mediated inflammatory disease with heterogeneity regarding its clinical features, mainly affecting the skin and the musculoskeletal system; additionally, extra-musculoskeletal manifestations and comorbidities are common, adding complexity to its treatment. In the last decades, a plethora of therapeutic options have been available, including conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs), and many recommendations have been published regarding the proper use of them in patients with PsA. In rheumatoid arthritis, the combination of conventional with bDMARDs or tsDMARDs is a common and recommended practice, whereas in PsA there is scarce data about the benefit of this combination. This review summarizes all the available data from randomized clinical trials, observational studies, and registries about the value of this therapeutic strategy. Competing Interests: The authors declare that there is no conflict of interest. (© The Author(s), 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|